Season 3 of Surfing The NASH Tsunami

S3-E63.2 - Year-End Interview with Stephen Harrison

S3-E63.2 – Year-End Interview with Stephen Harrison

In the Season 3 NAFLD Year-in-Review conversations series, Surfers Jörn Schattenberg, Louise Campbell and Roger Green embark on a string of interviews with a handful of Key Opinion Leaders who made headlines and advances in Fatty Liver disease in 2022.

S3-E63.1 - Year-End Interview with Naim Alkhouri

S3-E63.1 – Year-End Interview with Naim Alkhouri

In the Season 3 NAFLD Year-in-Review conversations series, Surfers Jörn Schattenberg, Louise Campbell and Roger Green embark on a string of interviews with a handful of Key Opinion Leaders who made headlines and advances in Fatty Liver disease in 2022. In this exclusive segment, Naim Alkhouri joins Louise and Roger to discuss drugs, NITs, digital diagnostics and the importance of preventing pediatric and adolescent NAFLD.

S3-E63 - 2022 NAFLD Year-in-Review Interview Series, Part 3

S3-E63 – 2022 NAFLD Year-in-Review Interview Series, Part 3

Surfing the NASH Tsunami hosts its annual NAFLD Year-in-Review over the second half of December. For the final installment of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Naim Alkhouri, Stephen Harrison and Ian Rowe to discuss putting a dent in Fatty Liver disease in 2022 and beyond.

S3-E62.3 - Year-End Interview with Jeff Lazarus

S3-E62.3 – Year-End Interview with Jeff Lazarus

Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Louise Campbell and Roger Green are joined by Jeff Lazarus to discuss a “drugs-plus” approach to liver disease, interprofessional collaboration, guidelines and much more.

S3-E62.2 - Year-End Interview with Ken Cusi

S3-E62.2 – Year-End Interview with Ken Cusi

Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Louise Campbell and Roger Green are joined by Ken Cusi to discuss two major trends: publication and adoption of guidelines and clinical care pathways that increase requirements from screening in primary care and endocrinology settings, and promising Phase 3 trials that suggest new NASH drugs are on a shorter-term horizon.

S3-E62.1 - Year-End Interview with Mazen Noureddin

S3-E62.1 – Year-End Interview with Mazen Noureddin

Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Mazen Noureddin to reflect on opening a new research institute, increasing optimism around drug trials and the use of NITs, work in the novel mitochondrial uncoupling agent HU6, the NAIL-NIT consortium and more.

S3-E62 - 2022 NAFLD Year-in-Review Interview Series, Part 2

S3-E62 – 2022 NAFLD Year-in-Review Interview Series, Part 2

Surfing the NASH Tsunami hosts its annual NAFLD Year-in-Review over the second half of December. For the second installment of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Mazen Noureddin, Ken Cusi and Jeff Lazarus to discuss putting a dent in Fatty Liver disease in 2022 and beyond.

S3-E60.5 - Madrigal Announcement on Resmetirom: Combination Therapy and Closing Takeaways

S3-E60.5 – Madrigal Announcement on Resmetirom: Combination Therapy and Closing Takeaways

Madrigal announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. This final conversation discusses what the announcement could mean for combination therapy and adjacent drug development stories. Each panelist provides closing thoughts to the session, offering diverse perspectives and an array of key takeaways.

S3-E61 - NASH-TAG 2023 Preview with Stephen Harrison

S3-E61 – NASH-TAG 2023 Preview with Stephen Harrison

A highly anticipated NASH-TAG 2023 takes place in Park City, Utah on January 5-7, 2023. In this episode, Stephen Harrison previews the conference agenda and shares his perspective on Madrigal’s announcement of positive topline results from the MAESTRO-NASH trial of resmetirom.

S3-E60.3 - Madrigal Announcement on Resmetirom: Diving into Implications

S3-E60.3 – Madrigal Announcement on Resmetirom: Diving into Implications

This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. This conversation dives into the implications of the Madrigal program, offering compelling commentary from a group of eight panelists with varying perspectives and takeaways.

S3-E60.2 - Madrigal Announcement on Resmetirom: First Reactions and Differing Perspectives

S3-E60.2 – Madrigal Announcement on Resmetirom: First Reactions and Differing Perspectives

This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. To commemorate what is primed to be a major breakthrough for the field, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the emerging story. This conversation offers varying first impressions and perspectives from the group of eight.

S3-E59.3 - Year-End Interview with Donna Cryer

S3-E59.3 – Year-End Interview with Donna Cryer

Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. In this installment, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Donna Cryer to discuss GLI’s preparations for a promising 2023, promoting patient perspectives, liver health awareness and much more.

S3-E59.2 - Year-End Interview with Hannes Hagström

S3-E59.2 – Year-End Interview with Hannes Hagström

Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. In this feature, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Hannes Hagström to discuss his studies in 2022 and beyond. Hannes provides an insight-laden tour of the myriad of research directions derived from a population-based cohort of liver disease patients in Sweden.

S3-E59.1 - Year-End Interview with Scott Friedman

S3-E59.1 – Year-End Interview with Scott Friedman

Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this first installment, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Scott Friedman to discuss the year in review, advancements in liver science, and more.

S3-E59 - 2022 NAFLD Year-in-Review Interview Series, Part 1

S3-E59 – 2022 NAFLD Year-in-Review Interview Series, Part 1

Surfing the NASH Tsunami hosts its annual NAFLD Year-in-Review over the second half of December. For the first installation of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Scott Friedman, Hannes Hagström and Donna Cryer to discuss putting a dent in Fatty Liver disease in 2022 and beyond.

S3-E58.1 - Returning to In-Person Meetings and Emerging News on NICE and FibroScan

S3-E58.1 – Returning to In-Person Meetings and Emerging News on NICE and FibroScan

Surfing the NASH Tsunami hosts its third NAFLD Year-in-Review – our look at key highlights of 2022. This conversation features the impressions of Jörn Schattenberg, Louise Campbell and Roger Green on returning to in-person meetings and the expectation that NICE is primed to approve FibroScan for primary care under specific circumstances.

S3-E58 - Surfing 2022: NAFLD Year-in-Review

S3-E58 – Surfing 2022: NAFLD Year-in-Review

Surfing the NASH Tsunami hosts its third NAFLD Year-in-Review – our look at key highlights of 2022 featuring the impressions of Jörn Schattenberg, Louise Campbell and Roger Green. This discussion looks at the return to in-person conferences and events, NICE on FibroScan, progress in NITs, potential pathway developments and much more.

S3-E57.5 - From the Vault: “Seeing what Should Be” – Imaging the Liver To Assess Functioning Hepatocytes

S3-E57.5 – From the Vault: “Seeing what Should Be” – Imaging the Liver To Assess Functioning Hepatocytes

In this episode From the Vault, Antaros Medical’s Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his 2021 Paris NASH talk. This conversation revolves around the implications of Lars’s comment that we should track and analyze functioning hepatocyte cells as an excellent marker for liver function.

S3-E57.4 - Discussing Critical Success Factors for Placebo Cohorts

S3-E57.4 – Discussing Critical Success Factors for Placebo Cohorts

In discussing the Liver Forum, Executive Director Veronica Miller joins guest Manal Abdelmalek, co-host Jörn Schattenberg and Roger Green to investigate how to study efficacy and safety in real time, using collective knowledge and experience with therapies for advancing liver disease. In this final conversation, Veronica, Manal and Jörn each provide their unique perspectives on critical success factors for placebo cohorts.

S3-E57 - The Liver Forum: Fighting Fatty Liver Using Collective Knowledge and Experience

S3-E57 – The Liver Forum: Fighting Fatty Liver Using Collective Knowledge and Experience

In this episode discussing the Liver Forum, Jörn Schattenberg, Manal Abdelmalek, Veronica Miller and Roger Green investigate how to study efficacy and safety in real time, using collective knowledge and experience with therapies for advancing liver disease. Jörn, Manal and Veronica each provide their unique introductions to the steering committee and elaborate on the Forum’s efforts toward moving the field forward.

S3-E56.4 - Integrated Solutions for Improved Patient Support

S3-E56.4 – Integrated Solutions for Improved Patient Support

Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. In this conversation, she joins Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green to discuss integrated solutions to provide more information and better support to patients.

S3-E56.2 - Setting and Driving Realistic Goals, and Dietician Visits as a Life-Long Therapy

S3-E56.2 – Setting and Driving Realistic Goals, and Dietician Visits as a Life-Long Therapy

Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. This conversation continues in the theme of weight reduction for NASH resolution, and strategies for long-term adherence to lifestyle modifications. Shira describes her own approach, termed weight-inclusive, which focuses on holistic coaching measures which extend to all facets of a happy and healthy lifestyle.

S3-E56.1 - Weight Reduction for NASH Resolution: Strategies for Long-Term Adherence to Lifestyle Modifications

S3-E56.1 – Weight Reduction for NASH Resolution: Strategies for Long-Term Adherence to Lifestyle Modifications

Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing alongside are panelists Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green. This conversation introduces the topic of weight reduction for NASH resolution, and strategies for long-term adherence to lifestyle modifications.

S3-E56 - Focus on the Intersection of Nutrition and NASH

S3-E56 – Focus on the Intersection of Nutrition and NASH

Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing alongside are Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green in this rich, applicable and fascinating discussion.

S3-E55.5 - Pediatric and Lean NASH: Learning from Diverse Populations

S3-E55.5 – Pediatric and Lean NASH: Learning from Diverse Populations

A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This final conversation discusses the diversity of populations with NASH before closing with the group’s predictions into a new year in the field of Fatty Liver disease.

S3-E55.4 - Emerging Roles for ELF Test and Advances in Use of PPARs

S3-E55.4 – Emerging Roles for ELF Test and Advances in Use of PPARs

A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This conversation explores emerging roles for the ELF test and advances in the use of PPARs.

S3-E55.3 - NIT Efficacy in Primary Care and Diabetes Clinic Settings

S3-E55.3 – NIT Efficacy in Primary Care and Diabetes Clinic Settings

A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This conversation focuses around the efficacy of NITs for identifying fatty liver disease and progression in primary care and diabetes clinic settings.

S3-E55.2 - Comparing Global Health Systems, Standardizing AST and Educating on NAFLD Prevalence

S3-E55.2 – Comparing Global Health Systems, Standardizing AST and Educating on NAFLD Prevalence

A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This conversation addresses several topics surrounding the importance of educating physicians on NAFLD prevalence in different systems around the globe, and key points around standardizing AST.

S3-E55 - 2022 AASLD Wrap-Up: Reviewing a Momentous Meeting

S3-E55 – 2022 AASLD Wrap-Up: Reviewing a Momentous Meeting

Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green convene to recap the just-concluded 2022 AASLD Liver Meeting. The panelists touch on a range of topics from a particularly momentous event which saw many promising papers presaging an exciting upcoming year for the field of Fatty Liver.

S3-E54.4 - An Interview with Michael Cooreman, CMO of Inventiva

S3-E54.4 – An Interview with Michael Cooreman, CMO of Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. In an exclusive interview, Chief Medical Officer Michael Cooreman joins Stephen Harrison and Roger Green to talk in depth about the company and key elements of its clinical development strategy for its pan-PPAR, lanifibranor.

S3-E54.3 - Exploring Mitochondrial Uncouplers in NASH and a Reanalysis of REGENERATE Study's Phase 3 Results

S3-E54.3 – Exploring Mitochondrial Uncouplers in NASH and a Reanalysis of REGENERATE Study’s Phase 3 Results

Surfing the NASH Tsunami hosted two recording sessions throughout the Liver Meeting to discuss key takeaways. This conversation is a composite featuring impressions from both sessions. In the first session, panelists review the emerging role of mitochondrial uncouplers in the field of NASH. The following session offers insight from a reanalysis of results from Intercept’s Phase 3 REGENERATE Study of Obeticholic Acid.

S3-E54.2 - Presentation on Efruxifermin in NASH with Fibrosis

S3-E54.2 – Presentation on Efruxifermin in NASH with Fibrosis

On the final morning of the 2022 AASLD Liver Meeting, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discussed their key takeaways and impressions. Stephen leads this conversation to highlight his presentation of results from Akero Therapeutics’ Phase 2b HARMONY Study.

S3-E54.1 - Utilizing Best Practices in Diagnostics

S3-E54.1 – Utilizing Best Practices in Diagnostics

The 73rd Annual AASLD Liver Meeting proved to be a lively and momentous event held in Washington DC. On the final morning, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe and Jeff McIntyre joined Roger Green to discuss key takeaways and impressions. In this conversation, the panelists focus on utilizing best practices in diagnostics.

S3-E53.1 - The Gut Microbiome and Complexities of NAFLD

S3-E53.1 – The Gut Microbiome and Complexities of NAFLD

Scott Friedman, Jörn Schattenberg, Rachel Zayas and Roger Green discuss takeaways from the first three days at the 73rd Annual Liver Meeting on site in Washington DC. In this conversation, the group dives into the gut microbiome while discussing the complex nature of NAFLD.

S3-E54 - AASLD 2022 Liver Meeting Live Coverage: Part 2

S3-E54 – AASLD 2022 Liver Meeting Live Coverage: Part 2

Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discuss key takeaways on the final morning of the 73rd Annual AASLD Liver Meeting. The group embarks on a far reaching conversation to cover at length topics including tests, drugs and nomenclature amongst many more impressions. Following the review, Roger and Stephen interview Michael Cooreman from Inventiva to discuss the focus of the clinical-stage biopharmaceutical company and its relevance to the field of Fatty Liver.

S3-E52.5 - 2022 AASLD Preview: Final Thoughts

S3-E52.5 – 2022 AASLD Preview: Final Thoughts

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in finalizing a second preview of key presentations and posters of interest.

S3-E52.4 - Exploring the NAFLD-Metabolic Link Through Screening Tools

S3-E52.4 – Exploring the NAFLD-Metabolic Link Through Screening Tools

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. This conversation explores abstracts on the NAFLD-Metabolic link and continues discussion around optimal screening tools.

S3-E52.3 - Remote Wellness Tools and Disease Management

S3-E52.3 – Remote Wellness Tools and Disease Management

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. In this conversation, the panelists explore the potential of remote wellness tools.

S3-E52.2 - Efficacy of NITs and Predictive Outcomes

S3-E52.2 – Efficacy of NITs and Predictive Outcomes

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. In this session, Ian shifts discussion toward the efficacy of various NITs and their predictive outcomes.

S3-E52.1 - FIB-4 and the Way Forward in Primary Care Screening

S3-E52.1 – FIB-4 and the Way Forward in Primary Care Screening

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. In this session, Mazen leads discussion on the way forward in diagnosing fibrotic NASH in patients with Type 2 Diabetes.

S3-E52 - Part 2: A Preview of the 2022 AASLD Liver Meeting

S3-E52 – Part 2: A Preview of the 2022 AASLD Liver Meeting

In a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green to discuss key presentations and posters of interest at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

S3-E51.5 - From the Vault: AASLD 2021 Wrap-up

S3-E51.5 – From the Vault: AASLD 2021 Wrap-Up

The 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th, 2022 in Washington DC. In this episode From the Vault, Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join Stephen Harrison, Louise Campbell and Roger Green to promptly recap a just-concluded 2021 AASLD Annual Liver Meeting. Discussion centers around the many areas of advance and novelty in the program, with particular attention to non-invasive testing, genomics and the increased visibility of patients and their needs.

S3-E51.4 - Discussing the NAFLD-Cancer Link and Fatty Liver Awareness

S3-E51.4 – Discussing the NAFLD-Cancer Link and Fatty Liver Awareness

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest. This conversation discusses the NAFLD-Cancer link and the importance of raising Fatty Liver awareness.

S3-E51.3 - AASLD 2022: A Preview of Patient Advocate Coverage on Liver Health Equity

S3-E51.3 – AASLD 2022: A Preview of Patient Advocate Coverage on Liver Health Equity

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest. This conversation explores patient advocate coverage of challenges facing liver health equity.

S3-E51.2 - Fibrosis Progression Rates for Diabetic vs. Non-Diabetic Patients

S3-E51.2 – Fibrosis Progression Rates for Diabetic vs. Non-Diabetic Patients

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest. This conversation focuses on fibrosis progression rates for diabetic vs. non-diabetic patients.

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud